Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sebetralstat - KalVista Pharmaceuticals

Next Previous
Drug Profile

Sebetralstat - KalVista Pharmaceuticals

Alternative Names: EKTERLY; KVD-900

Latest Information Update: 30 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vantia Therapeutics
  • Developer KalVista Pharmaceuticals
  • Class Amines; Aza compounds; Esters; Pyrazoles; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Plasma kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema

Most Recent Events

  • 25 Jul 2025 Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issues a positive opinion and recommends marketing authorisation approval of sebetralstat for Hereditary angioedema (In adolescents, In adults)
  • 25 Jul 2025 KalVista Pharmaceuticals expects a final decision from the European Commission (EC) regarding approval of marketing authorisation of sebetralstat for Hereditary angioedema (In adolescents, In adults), by early October 2025
  • 15 Jul 2025 KalVista anticipates a decision from the National Institute for Health and Care Excellence (NICE) for use of EKTERLY under the UK’s National Health Service (NHS) in the first half of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top